Literature DB >> 24669018

Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer.

M Kwon1, J-L Roh2, J Song3, S-W Lee4, S-B Kim5, S-H Choi1, S Y Nam1, S Y Kim6.   

Abstract

BACKGROUND: The survival of patients with head and neck squamous cell carcinoma (HNSCC) can be affected by noncancer health events (NCHE) as well as by index cancer progression and second primary cancer (SPC). This study aimed to investigate the risk factors for NCHE and noncancer mortality (NCM) in patients with advanced-stage HNSCC. PATIENTS AND METHODS: This cohort study involved 600 consecutive patients with overall stage III to IV HNSCC who were treated between 2001 and 2010 at our tertiary referral hospital. NCHE was defined as re-admission (i.e. after the primary treatments for the index tumors) due to noncancer-related causes. The incidences of NCHE and NCM and their risk factors were analyzed by using cumulative incidence and cause-specific hazard functions.
RESULTS: During a median follow-up period of 54 months, 224 (37.3%) and 55 (9.2%) of the 600 patients had NCHE and NCM, respectively. The 5-year index cancer mortality, SPC mortality, and NCM rates were 23.8%, 4.2%, and 8.9%, respectively. Multivariate analyses revealed that body mass index <20 kg/m(2) (P = 0.018), Charlson comorbidity index (CCI) ≥1 (P < 0.001), tumor recurrence (P < 0.001), SPC occurrence (P < 0.001), and initial chemotherapy (P = 0.049) were independent NCHE predictors. Older age (P < 0.001), CCI ≥1 (P = 0.008), tumor recurrence (P < 0.001), and SPC occurrence (P = 0.047) were independent NCM predictors. Patients with respiratory NCHE were at a higher risk of NCM than patients with other NCHE types (P < 0.001).
CONCLUSIONS: One or more comorbidities, tumor recurrence, and SPC occurrence were independent predictors of both NCHE and NCM. Patients with respiratory NCHE had a particularly high risk of NCM.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  comorbidities; competing mortalities; head and neck squamous cell carcinoma; noncancer health event; risk factors

Mesh:

Year:  2014        PMID: 24669018     DOI: 10.1093/annonc/mdu128

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Authors:  Loren K Mell; Hanjie Shen; Phuc Felix Nguyen-Tân; David I Rosenthal; Kaveh Zakeri; Lucas K Vitzthum; Steven J Frank; Peter B Schiff; Andy M Trotti; James A Bonner; Christopher U Jones; Sue S Yom; Wade L Thorstad; Stuart J Wong; George Shenouda; John A Ridge; Qiang E Zhang; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2019-08-16       Impact factor: 12.531

2.  Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma.

Authors:  Eric Adjei Boakye; Paula Buchanan; Leslie Hinyard; Nosayaba Osazuwa-Peters; Mario Schootman; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

3.  Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.

Authors:  Minsu Kwon; Jong-Lyel Roh; Jihyun Song; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam
Journal:  Oncologist       Date:  2015-03-23

4.  Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.

Authors:  Collin F Mulcahy; Abdallah S R Mohamed; Aasheesh Kanwar; Katherine A Hutcheson; Alokananda Ghosh; David Vock; Randal S Weber; Stephen Y Lai; Gary Brandon Gunn; Mark Zafereo; William H Morrison; Renata Ferrarotto; Adam S Garden; David I Rosenthal; Clifton D Fuller
Journal:  Head Neck       Date:  2018-05-13       Impact factor: 3.147

5.  Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.

Authors:  Jun Woo Park; Jong-Lyel Roh; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-07       Impact factor: 4.553

6.  An Introduction to a Head and Neck Cancer-Specific Frailty Index and Its Clinical Implications in Elderly Patients: A Prospective Observational Study Focusing on Respiratory and Swallowing Functions.

Authors:  Minsu Kwon; Shin-Ae Kim; Jong-Lyel Roh; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Oncologist       Date:  2016-07-01

7.  Multilevel Associations Between Patient- and Hospital-Level Factors and In-Hospital Mortality Among Hospitalized Patients With Head and Neck Cancer.

Authors:  Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Betty Chen; Miao Cai; Betelihem B Tobo; Sai D Challapalli; Paula Buchanan; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

8.  Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.

Authors:  Ruben Carmona; Kaveh Zakeri; Garrett Green; Lindsay Hwang; Sachin Gulaya; Beibei Xu; Rohan Verma; Casey W Williamson; Daniel P Triplett; Brent S Rose; Hanjie Shen; Florin Vaida; James D Murphy; Loren K Mell
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

9.  Radiotherapy for locally advanced head and neck cancer in elderly patients: results and prognostic factors a single cohort.

Authors:  Gustavo Arruda Viani; Alexandre Ciufi Faustino; Anielle Freitas Bendo Danelichen; Fernando Kojo Matsuura; Leonardo Vicente Fay Neves; Marco Henrique Fernandes; Juliana Pavoni Fernandes
Journal:  Rep Pract Oncol Radiother       Date:  2021-02-25

10.  Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study.

Authors:  Raghav Tripathi; Anthony P Fernandez
Journal:  Arch Dermatol Res       Date:  2020-08-17       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.